SAN DIEGO--(BUSINESS WIRE)--Ambit Biosciences today announced that the company has expanded the panel of kinases available through its KinomeScan profiling technology to 317 from 256. The newly added assays include several therapeutically relevant wild-type and mutant kinases, including phosphoinositide-3-kinase (PI3K), a lipid kinase target for oncology. The expanded KinomeScan panel now represents the largest and most comprehensive profiling panel of its kind.
